CompoAtlas

Whitening Belle & Bio

Food supplement declared in France, decision dated 27 August 2026

Whitening Belle & Bio is a food supplement declared in France. Status: déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité). 1 rule of use applies to its ingredients (limits and warnings).

Brand
not provided
Food business operator placing the product on the market
BELLE & BIO (BELLE & BIO)
Status
Déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité)
Form
Gélule
Daily dose
2
Objectives stated by the manufacturer (these are not authorised claims)
Peau

Declaration 374212, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.

Regulatory points

Declared composition

Plants

PlantPartPreparationPer day
Solanum lycopersicum L.FruitExtrait sec aqueux200 mg
Vitis vinifera L.PépinExtrait sec aqueux66.66 mg
Vitis vinifera L.FruitPoudre (de plantes séchées ou broyées)33.34 mg
Glycyrrhiza glabra L.RacineExtrait sec aqueux33.34 mg

Substances

NamePer day
acide lipoïquenot declared

Other active ingredients

NamePer day
Membrane d'oeufnot declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
NicotinamideNicotinamide (vitamine B3)900 mg54 mg
Acide L-ascorbiqueVitamine Cpas de limite (données insuffisantes)180 mg
Citrate de zincZinc25 mg15 mg

Additives

E551, E470b

Other ingredients

gélatine

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Label warnings

Ne pas utiliser pendant plus de 6 semaines sans avis médical. Déconseillé en cas d’hypertension artérielle, de pathologies cardiaques ou rénales, d’insuffisance hépatique, et de tout trouble de l’équilibre hydro-électrolytique ; en cas de traitements médicamenteux, demander conseil à un professionnel de santé ; aux femmes enceintes et allaitantes ; réservé aux adultes. Éviter le cumul des sources de réglisse.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Glycyrrhiza glabra L.
    Read the warning, when it applies and the studies cited

    DEGLYCYRRHIZINATED LICORICE Buccal

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 31 October 2025

    Deglycyrrhizinated Licorice Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 31 January 2025

    LICORICE

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (Gardner and McGuffin 2013).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Cough relief.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if cough worsens or persists (for) more than 1 week (EMA 2012).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Gastritis relief.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Contraindications

    Condition of application: All products.

    Do not use if you are pregnant (EMA 2012).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Do not use if you have hypokalemia, high blood pressure, or a kidney, liver or cardiovascular disorder (EMA 2012; Brinker 2010; ESCOP 2003; Bradley 1992).

    4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Do not use if you are taking heart medications, corticosteroids, stimulant laxatives, or other health products that may contribute electrolyte imbalance (Brinker 2010; ESCOP 2003; Hoffmann 2003; Blumenthal et al. 2000).

    4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 29 November 2024

  • acide lipoïque
    Read the warning, when it applies and the studies cited

    DL-ALPHA-LIPOIC ACID/R-ALPHA-LIPOIC ACID

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Jacob et al. 1999, Konrad et al. 1999, Packer et al. 1995).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Applies to products providing 42 milligrams or more DL-alpha-lipoic acid or 21 milligrams or more R-alpha-lipoic acid, per day.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience sweating, paleness, chills, headache, dizziness and/or confusion (as these may be symptoms of serious low blood sugar) (Bae et al., 2013; Gullo et al., 2014; Bresciani et al., 2011; Chang et al., 2009).

    4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 27 June 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line